Involvement of patients and consumers in the Agency's activities
Patients and consumers are the end-users of the medicines that the European Medicines Agency evaluates, so they are key stakeholders with specific knowledge and expertise to offer the Agency.
The Agency is committed to maintaining a strong working relationship with patients and consumers and is interacting with a growing number of patients’ and consumers’ organisations.
See more information on the Agency's work with patients and consumers.
Searching for medicines by therapeutic area
It is possible to browse for a medicine by therapeutic area. The Agency categorises each medicine it assesses using a taxonomy which can be easily browsed. Go to European public assessment reports (EPARs) and use the 'browse by therapeutic area' tab.
Beware of falsified medicines!
Falsified medicines are fake medicines that may enter the supply chain illegally. Be careful about the way you buy medicines. Find more information on falsified medicines.
Search for herbal medicines
The Agency is responsible for supporting the harmonisation of herbal medicinal products in Europe. Search for herbal medicines assessed by the Agency's Committee on Herbal Medicinal Products.
News for patients and carers
This page provides an overview of the opinions adopted at the July 2014 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes. ... Read more
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), at its July meeting, recommended granting marketing authorisations for two new medicines with novel mechanisms of action for the treatment of different forms of rare cancers of the blood. ... Read more
World Hepatitis Day – European Medicines Agency uses regulatory tools to facilitate patient access to innovative medicines
According to the World Health Organization (WHO), viral hepatitis kills 1.4 million people worldwide every year. ... Read more
The European Medicines Agency has today launched a public consultation on draft rules of procedures for public hearings held by its Pharmacovigilance Risk Assessment Committee (PRAC). ... Read more
Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight
The European Medicines Agency has concluded its review of emergency contraceptives containing levonorgestrel or ulipristal acetate to assess whether increased bodyweight affects the effectiveness of these medicines in preventing unintended pregnancy following unprotected sexual intercourse or contraceptive failure. ... Read more
- See all News for patients and carers
Events of interest
European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting
This is a joint meeting with representatives from patients’, consumers’ and healthcare professionals’ organisations. Participants will be updated on a number of EMA initiatives including EMA adaptive licensing pilot project, HTA-EMA interaction, assessing the impact of pharmacovigilance and EMA communication on medication errors. The PCWP/HCPWP work programmes 2015 will also be discussed. Registration by invitation only. ... Read more
European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting - Workshop on benefit-risk communication
This is a joint Workshop with representatives from patients', consumers' and healthcare professionals' organisations. The workshop will provide an overview of how EMA communicates on the benefits and risks of medicines within the EU regulatory network. It will also discuss the role of communication in achieving effectiveness of risk minimisation measures and explore how such communication can support healthcare professionals and patients on their treatment decisions. Registration by invitation only. ... Read more
This event aims to promote communication between national competent authorities and patient and healthcare-professional organisations, providing an overview on the latest norms and guidelines on clinical trials and an introduction to the pharmacovigilance legislation. It aims to serve also as a platform for networking between local organisations and authorities in order to promote further activities and cooperation. It is supported by the European Commission and organised in collaboration with the Medicines and Medical Devices Agency of Serbia as a final event prior the closure of the Instrument for Pre-accession I Programme. Registration by invitation only. ... Read more
Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) workshop on advanced-therapy medicinal products: How to bring cell-based medicinal products successfully to the market
The workshop is co-organised by the European Medicines Agency's (EMA's) Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) in collaboration with the German Stem Cell Network (GSCN) and aims to strengthen dialogue between CAT and the advanced-therapy-medicinal-product (ATMP) developers in industry, academia and hospitals and to facilitate ATMP development and access to the registration procedure. The workshop will allow for the attendees to learn about the development and authorisation of cell-based ATMPs in the European Union and the role of the CAT; to learn about the support provided by EMA and the CAT to ATMP developers; to understand the criteria that CAT applies for the classification of ATMPs; and to hear about CAT’s considerations and recent interactions with experts on cell-based therapies for cardiac repair. It will also allow to interact directly with the Regulators in an open forum discussion. ... Read more
04/12/2014 - 05/12/2014
European Medicines Agency (EMA)/European Federation of Pharmaceutical Industries and Associations (EFPIA) workshop on the importance of dose finding and dose selection for the successful development, licensing and lifecycle management of medicinal products
A European Medicines Agency (EMA)/European Federation of Pharmaceutical Industries and Associations (EFPIA) workshop is planned for 4-5 December 2014 to discuss the importance of dose finding and dose selection for the successful development, licensing and lifecycle management of medicinal products. Registration: please register by 19 September 2014 using the registration form provided. ... Read more
- See all Events of interest